Trials / Unknown
UnknownNCT03596749
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4: a Protocol of a Randomized, Parallel, Controlled Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Fan Fan Hou · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate effects of sevelamer carbonate on reducing TMAO in stage 3b-4 CKD (pre-dialysis) patients. The study will also investigate the safety and tolerability of sevelamer carbonate in study population and the effects of sevelamer carbonate on serum p-cresyl sulfate, indoxyl sulfate, LDL-C and uric acid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sevelamer Carbonate | Sevelamer carbonate 1600mg (p.o. b.i.d) with meals |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2019-05-01
- Completion
- 2019-07-01
- First posted
- 2018-07-24
- Last updated
- 2018-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03596749. Inclusion in this directory is not an endorsement.